Stanley A. Knight

Stanley Knight serves as a Contracting Officer responsible for managing complex acquisition programs centered on scientific and technical research services. In this role, he ensures compliance with federal procurement regulations while advancing mission-critical R&D objectives across physical, engineering, and life sciences domains. His portfolio primarily involves soliciting and awarding contracts for laboratory services, analytical instrumentation, clinical research support, and advanced technology development. Knight operates with a strong emphasis on technical rigor, ensuring that solicitation documents clearly define performance requirements and evaluation criteria to attract qualified, high-performing vendors. While no specific contractor relationships are currently identifiable in the data, Knight’s procurement patterns suggest consistent engagement with research-focused firms capable of delivering high-complexity scientific services. He typically works with a mix of large prime contractors and specialized small businesses possessing deep domain expertise in experimental design, data analysis, and laboratory operations. His contracting approach emphasizes competitive sealed bidding and negotiated procurements under FAR Part 15, prioritizing technical merit and past performance over price alone. Knight demonstrates a strong preference for open competition, with 100% of his acquisitions classified as “No Set-Aside.” This reflects a strategic focus on sourcing the most technically capable performers regardless of socioeconomic status, rather than leveraging set-aside programs. While he does not prioritize 8(a), HUBZone, or SDVOSB set-asides, his actions remain fully compliant with all small business participation goals through unrestricted competition. His primary procurement focus lies in NAICS 541712 (Research and Development in the Physical, Engineering, and Life Sciences) and NAICS 541714 (Research and Development in Biotechnology), indicating deep expertise in procuring services related to laboratory research, clinical trials, molecular analysis, and biotechnological innovation. He routinely acquires specialized equipment, computational modeling services, and contract research organization (CRO) support to advance federal scientific initiatives.